UroGen Pharma(URGN) Prnewswire·2025-06-06 09:45Core Viewpoint - A class action securities lawsuit has been filed against UroGen Pharma Ltd. due to alleged securities fraud affecting investors between July 27, 2023, and May 15, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that UroGen Pharma Ltd. made false statements regarding the ENVISION clinical study, which was not adequately designed to demonstrate the effectiveness of its lead product, UGN-102, due to the absence of a concurrent control arm [2]. - It is alleged that UroGen Pharma Ltd. failed to address FDA warnings about the study design, leading to a significant risk that the New Drug Application (NDA) for UGN-102 would not be approved [2]. - The lawsuit asserts that the positive statements made by the defendants about the company's business and prospects were materially misleading and lacked a reasonable basis [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until July 28, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].